KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Opko Health (OPK) Gains from Sales and Divestitures (2023 - 2025)

Opko Health's Gains from Sales and Divestitures history spans 3 years, with the latest figure at $850146.0 for Q4 2025.

For Q4 2025, Gains from Sales and Divestitures rose 54.66% year-over-year to $850146.0; the TTM value through Dec 2025 reached $850146.0, up 54.66%, while the annual FY2025 figure was $850146.0, 54.66% up from the prior year.
Gains from Sales and Divestitures reached $850146.0 in Q4 2025 per OPK's latest filing, up from $549687.0 in the prior quarter.
In the past five years, Gains from Sales and Divestitures ranged from a high of $850146.0 in Q4 2025 to a low of $549680.0 in Q4 2023.
Average Gains from Sales and Divestitures over 3 years is $649837.7, with a median of $549687.0 recorded in 2024.
Peak YoY movement for Gains from Sales and Divestitures: grew 0.0% in 2024, then soared 54.66% in 2025.
A 3-year view of Gains from Sales and Divestitures shows it stood at $549680.0 in 2023, then increased by 0.0% to $549687.0 in 2024, then skyrocketed by 54.66% to $850146.0 in 2025.
Per Business Quant, the three most recent readings for OPK's Gains from Sales and Divestitures are $850146.0 (Q4 2025), $549687.0 (Q4 2024), and $549680.0 (Q4 2023).